Document 0866
 DOCN  M95A0866
 TI    Trial objectives and end points for measuring the efficacy of HIV
       vaccines.
 DT    9510
 AU    Hoff R; Barker LF; Vaccine and Prevention Research Program, Division of
       AIDS,; National Institute of Allergy and Infectious Diseases, NIH,;
       Bethesda, Maryland 20892, USA.
 SO    Infect Agents Dis. 1995 Jun;4(2):95-101. Unique Identifier : AIDSLINE
       MED/95338451
 AB    In order to prove the efficacy of human immunodeficiency virus (HIV)
       vaccines, it will be necessary to do large-scale trials in populations
       at high risk of acquiring HIV infection. The choice of objectives and
       end points and their measurement will be key to the design of efficacy
       trials. To address these issues, the National Institute of Allergy and
       Infectious Diseases convened several workshops and discussions at
       national meetings. These discussions have concluded that many factors
       will contribute to the selection of practical primary objectives and end
       points for efficacy trials of HIV vaccines. For initial trials the
       objective of preventing the establishment of chronic infection is a
       reasonable choice, given the current state of knowledge. However, given
       the complexities of HIV and the acquired immunodeficiency syndrome, it
       will be important to collect data and evaluate other potential
       objectives and end points as well.
 DE    Acquired Immunodeficiency Syndrome/PREVENTION & CONTROL  AIDS
       Vaccines/*THERAPEUTIC USE  Clinical Trials  Drug Evaluation  Human  HIV
       Infections/*PREVENTION & CONTROL  JOURNAL ARTICLE  REVIEW  REVIEW,
       TUTORIAL

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).